ARA-290

ARA-290, also known by its investigational name cibinetide, is a synthetic 11-amino acid peptide derived from the tissue-protective domain of erythropoietin (EPO). Unlike native EPO, ARA-290 was deliberately engineered to strip out erythropoietic activity entirely, leaving only the tissue-protective signaling intact. This means it does not stimulate red blood cell production and carries none of the cardiovascular risks associated with elevated hematocrit.

The peptide's mechanism centers on the innate repair receptor (IRR), a heteromeric complex formed by the erythropoietin receptor (EPOR) and the beta-common receptor (betacR). This receptor complex is selectively upregulated in injured or inflamed tissue and is largely absent in healthy, uninjured cells. When ARA-290 binds to the IRR, it initiates anti-apoptotic signaling, suppresses local pro-inflammatory cytokine cascades, and inhibits death signals that would otherwise lead to cell loss.

Clinical research has evaluated ARA-290 most extensively in sarcoidosis-associated small fiber neuropathy (SFN). A randomized, placebo-controlled trial demonstrated that 4 mg subcutaneous daily injections over 28 days increased corneal nerve fiber density and significantly reduced neuropathic pain scores. A parallel metabolic study found improvements in insulin sensitivity and HbA1c in patients with type 2 diabetes. The FDA granted ARA-290 Orphan Drug status for neuropathic pain in sarcoidosis.

Preclinical research spans models of myocardial infarction, diabetic retinopathy, traumatic brain injury, burns, and shock-induced multi-organ failure. Human pharmacokinetic data shows a peak plasma concentration of roughly 3 ng/mL following a 4 mg subcutaneous dose, with a terminal half-life of approximately 20 minutes.